血清M30及M65对药物性肝损伤患者肝脏炎症的诊断价值

肝脏 ›› 2022, Vol. 27 ›› Issue (10): 1116-1119.

血清M30及M65对药物性肝损伤患者肝脏炎症的诊断价值

阚延婷, 吴卫锋, 杨永峰

210003 南京中医药大学附属南京医院,南京市第二医院肝病科

收稿日期:2021-12-01 出版日期:2022-10-31 发布日期:2022-11-22
通讯作者: 杨永峰,Email:yangyongfeng@njucm.edu.cn

Diagnostic value of serum M30 and M65 for liver inflammation in patients with drug-induced liver injury

KAN Yan-ting, WU Wei-feng, YANG Yong-feng

Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing Second Hospital, Jiangsu 210003, China

Received:2021-12-01 Online:2022-10-31 Published:2022-11-22
Contact: YANG Yong-feng, Email:yangyongfeng@njucm.edu.cn

摘要/Abstract

摘要： 目的明确血清M30及M65对药物性肝损伤患者肝脏炎症的诊断价值。方法选择2020年6月—2021年6月南京市第二医院肝病一科收治的39例药物性肝损伤患者,根据入院时肝脏炎症程度分为轻-中度组24例和重度组15例,并选取18例健康体检者作为对照组。采用酶联免疫吸附法(ELISA)检测药物性肝损伤患者及健康对照者血清M30及M65水平的差异,以及药物性肝损伤患者治疗前后的血清M30及M65水平变化,分析血清M30及M65水平与肝功能指标的相关性。结果轻-中度组及重度组的血清M30分别为(256.41 ± 50.61)U/L、(1116.69 ± 136.83)U/L,M65分别为(1007.98 ± 291.15)U/L、(3963.68 ± 614.62)U/L,均高于健康对照组(47.53 ± 5.69)U/L和(64.74 ± 5.25)U/L(P<0.05);重度组的血清M30、M65均高于轻-中度组(P<0.05);经过治疗肝脏炎症恢复后检测的M30与健康对照组比较无统计学差异(P>0.05),M65仍高于健康对照组,差异有统计学意义(P<0.05);M65与ALT(r=0.523,P<0.05)、AST(r=0.512,P<0.05)、γ-GT(r=0.434,P<0.05)及ALP(r=0.423,P<0.05)成正相关;M30与ALT(r=0.748,P<0.05)、AST(r=0.525,P<0.05)成正相关,而与γ-GT(r=0.325,P>0.05)及ALP(r=0.415,P>0.05)虽成正相关,但差异无统计学意义。结论血清M30、M65水平是反映药物性肝损伤患者肝细胞坏死和凋亡较灵敏的指标,与肝脏炎症相关,有一定的临床辅助价值。

关键词: 药物性肝损伤, M30, M65

Abstract: Objective To determine the diagnostic value of serum M30 and M65 for liver inflammation in patients with drug-induced liver injury (DILI). Methods From June 2020 to June 2021, 37 patients with drug-induced liver injury were selected from the First Department of Hepatology, Nanjing Second Hospital. According to the degree of liver inflammation at admission, they were divided into mild-moderate group (24 cases) and severe group (15 cases), and 18 healthy people were selected as control group. Enzyme-linked immunosorbent assay was used to detect the difference of serum M30 and M65 levels between DILI patients and healthy controls, and the changes of serum M30 and M65 levels before and after treatment. Analyzing the correlation between serum M30 and M65 levels and liver function indexes, including alaninetransaminase (ALT), aspartatetransaminase (AST), gamma-glutamyl transferase (γ-GT), alkaline phosphatase (ALP). Results Serum M30 in mild-moderate group and severe group were (256.41 ± 50.61) U/L and (1116.69 ± 136.83) U/L respectively, and serum M65 in mild-moderate group and severe group were (1007.98 ± 291.15) U/L and (3963.68 ± 614.62) U/L respectively, both were higher than healthy control group (P<0.05). After treatment, there was no significant difference between M30 detected after liver inflammation recovery and healthy control group (P>0.05), but M65 was still higher than that of healthy control group (P<0.05). M65 was positively correlated with ALT (r=0.523, P<0.05), AST (r=0.512, P<0.05), γ-GT (r=0.434, P<0.05) and ALP (r=0.423, P<0.05). M30 was positively correlated with ALT (r=0.748, P<0.05) and AST (r=0.525, P<0.05). There is a positive correlation with γ-GT (r=0.325, P>0.05) and ALP (r=0.415, P>0.05), but there is no statistical difference. Conclusion Serum M30 and M65 levels are sensitive indicators to reflect hepatocyte necrosis and apoptosis in patients with DILI, which are related to liver inflammation and have certain clinical auxiliary value.

Key words: Drug-induced liver injury, M30, M65

阚延婷, 吴卫锋, 杨永峰. 血清M30及M65对药物性肝损伤患者肝脏炎症的诊断价值[J]. 肝脏, 2022, 27(10): 1116-1119.

KAN Yan-ting, WU Wei-feng, YANG Yong-feng. Diagnostic value of serum M30 and M65 for liver inflammation in patients with drug-induced liver injury[J]. Chinese Hepatolgy, 2022, 27(10): 1116-1119.

参考文献

[1] 吴云辉,谢新生,邓敏. 血清M30和M65水平变化对乙型肝炎病毒相关慢加急性肝衰竭患者人工肝治疗短期预后的预测价值. 中华传染病杂志,2019,37(11):661-666.
[2] 魏建波,刘琴,蔡莹,等.ROC曲线评价M30和M65在非酒精性脂肪肝诊断中的价值. 浙江医学,2013,35(17):1593-1595.
[3] 陈晓栋,赵昱,温立婷,等. 耳鼻咽喉头颈外科住院总医师气管切开分析. 中国耳鼻咽喉头颈外科,2013,20(11):600-602.
[4] Beinchou C. Criteria of drug-induced liver disorders.Report 0f international.eoncellcus meetinglJJ. J HepatoL 1990,1l(2):272-276.
[5] Bateman AC, Hübscher SG. Cytokeratin expression as an aid to diagnosis in medical liver biopsies. Histopathology, 2010, 56(4):415-425.
[6] Eguchi A, Wree A, Feldstein AE. Biomarkers of liver cell death. J Hepatol, 2014, 60:1063‐1074.
[7] He L, Deng L, Zhang Q, et al. Diagnostic Value of CK‐18, FGF‐21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta‐Analysis. Biomed Res Int, 2017, 2017:9729107.
[8] Balkan A, Yilmaz N, Balkan Y, et al. Relationship between liver injury and serum cytokeratin 18 levels in asymptomatic hepatitis B virus carriers and in patients with chronic hepatitis B infection. Arab J Gastroenterol, 2017, 18 :98‐103.
[9] Rutherford A, King LY, Hynan LS, et al. Development of an accurate index for predicting outcomes of patients with acute liver failure. Gastroenterology, 2012,143(5):1237-1243.
[10] Sekiguchi T, Umemura T, Fujimori N, et al. Serum cell death biomarkers for prediction of liver fibrosis and poor prognosis in primary biliary cirrhosis. PloS one, 2015,10(6):e0131658.
[11] 郭世民,魏巍,张自然,等. 血清M30及 M 65水平用于HBV相关慢加急性肝衰竭患者预后的临床价值. 肝脏,2018,23(7):607-611.
[12] Joka D, Wahl K, Moeller S, et a1. Prospective biopsy—controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology,2012,55:455-464.

[1]	张舒, 喻志阳. 外周血白细胞端粒长度对抗结核药药物性肝损伤的预测价值[J]. 肝脏, 2022, 27(9): 1011-1014.
[2]	赖荣陶, 刘鸿凌, 陈成伟, 于乐成. 2022年美国肝病学会(AASLD)关于药物及草药和膳食补充剂(HDS)所致肝损伤的实践指导[J]. 肝脏, 2022, 27(8): 835-840.
[3]	王芳, 谢青, 赖荣陶. 首乌藤致亚急性肝功能衰竭1例[J]. 肝脏, 2022, 27(8): 940-940.
[4]	赖荣陶, 陈成伟, 阳文新, 于乐成. 药物性肝损伤因果关系评估量表:RECAM将取代RUCAM？[J]. 肝脏, 2022, 27(7): 725-729.
[5]	施莉琴, 周柳青, 张晓琴, 叶晴, 周计雪. 药物诱导的AIH-PBC重叠综合征1例[J]. 肝脏, 2022, 27(7): 829-830.
[6]	陈红, 赵莎莎, 杨婉君. 慢性药物性肝损伤患者临床特征及转归分析[J]. 肝脏, 2022, 27(6): 679-682.
[7]	赵娇, 肖丽. 170例药物性肝损伤患者临床特征分析[J]. 肝脏, 2022, 27(6): 683-687.
[8]	袁维, 黄杏, 曾雅雯, 石姣灵, 陈斌. 阿莫西林克拉维酸钾致药物性肝损伤1例及文献复习[J]. 肝脏, 2022, 27(4): 499-501.
[9]	张丽丽, 张润顺, 姚子昂, 胡建华, 吕文良. 药物相关性慢性肝衰竭患者临床特点分析[J]. 肝脏, 2022, 27(10): 1110-1111.
[10]	苏琼丽, 魏龙, 吴玲. 赛瑞替尼致肝损伤1例[J]. 肝脏, 2022, 27(10): 1151-1152.
[11]	黄嘉敏, 赵霞, 孙宜康, 李宛莹, 苟继周, 周光德, 何清. 何首乌致药物性肝损伤的病理学特点[J]. 肝脏, 2022, 27(1): 20-22.
[12]	武亭, 王艳, 刘立伟, 李柯鑫, 王昱, 欧晓娟, 贾继东, 赵新颜, 马红. 基础疾病负担对药物性肝损伤严重程度及预后的影响[J]. 肝脏, 2022, 27(1): 23-27.
[13]	惠磊, 李樱宁, 罗晶晶, 吴新安. 头孢呋辛致药物性肝损伤的自动监测与预测模型的建立及验证[J]. 肝脏, 2022, 27(1): 28-32.
[14]	崔大广, 肖玲燕, 刘永福, 史东阳, 杨凯, 郑以山. CTP-MELD评分联合血清M30和M65预测乙型肝炎相关慢加急性肝衰竭短期预后的价值[J]. 肝脏, 2022, 27(1): 58-62.
[15]	金承焕, 汪佳兵, 王石健. 华法林致药物性肝损伤1例及文献复习[J]. 肝脏, 2021, 26(9): 1054-1056.